Phase 3 Clinical Trial of D-Fi for RDEB

Date Updated
EB Type
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Name of Company
Paragon Biosciences
Recruitment Status
Recruiting
About the Study

The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.

Transportation, lodging, and a daily per diem for meals are provided; compensation for time may be provided.

Trial Entry Criteria
  • Male or female ≥2 years of age at the Screening visit
  • Clinical diagnosis of RDEB with confirmation of COL7A1 genetic mutation.

Get more information on ClinicalTrials.gov

Contacts & Location

If you have questions regarding this clinical trial, or if you are interested in participating, please contact the study coordinator for the locations listed below:

  • Santa Margarita, CA
    • Location: Mission Dermatology, Shireen Guide, MD
    • Study Coordinator: Kayla Kim 
  • Aurora, CO
  • Worcester, MA
    • Location: University of Massachusetts, Diana Reusch, MD
    • Study Coordinator: Celia Hartigan

Back to main Clinical Trials listing